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SAMHD1 is a key regulator of the lineage-specific
response of acute lymphoblastic leukaemias
to nelarabine
Tamara Rothenburger1, Katie-May McLaughlin2, Tobias Herold 3,4, Constanze Schneider1,10,
Thomas Oellerich5,6,7, Florian Rothweiler1, Andrew Feber 8, Tim R. Fenton 2, Mark N. Wass 2,
Oliver T. Keppler9, Martin Michaelis 2✉ & Jindrich Cinatl Jr. 1✉
The nucleoside analogue nelarabine, the prodrug of arabinosylguanine (AraG), is effective
against T-cell acute lymphoblastic leukaemia (T-ALL) but not against B-cell ALL (B-ALL). The
underlying mechanisms have remained elusive. Here, data from pharmacogenomics studies
and a panel of ALL cell lines reveal an inverse correlation between nelarabine sensitivity and
the expression of SAMHD1, which can hydrolyse and inactivate triphosphorylated nucleoside
analogues. Lower SAMHD1 abundance is detected in T-ALL than in B-ALL in cell lines
and patient-derived leukaemic blasts. Mechanistically, T-ALL cells display increased SAMHD1
promoter methylation without increased global DNA methylation. SAMHD1 depletion
sensitises B-ALL cells to AraG, while ectopic SAMHD1 expression in SAMHD1-null T-ALL
cells induces AraG resistance. SAMHD1 has a larger impact on nelarabine/AraG than on
cytarabine in ALL cells. Opposite effects are observed in acute myeloid leukaemia cells,
indicating entity-specific differences. In conclusion, SAMHD1 promoter methylation and, in
turn, SAMHD1 expression levels determine ALL cell response to nelarabine.
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Acute lymphoblastic leukaemia (ALL) cells originate fromprecursor lymphoid T- (T-ALL) and B-cells (B-ALL). Inchildren, ALL is the most common cancer associated with
high cure rates of about 85%. In adults, ALL accounts for 15–25%
of acute leukaemias and is associated with a less favourable
outcome1–4. Among ALLs, T-ALL is responsible for ~15% of
paediatric ALLs and 25% of adult ALLs3. Nelarabine displays
selective activity in T-ALL over B-ALL and is used for the treat-
ment of relapsed and refractory T-ALL but not routinely for the
treatment of B-ALL3,5–13. However, the molecular mechanisms
underlying this difference remain elusive. Moreover, nelarabine
therapy can be associated with irreversible life-threatening
neurotoxicity8,14. Hence, biomarkers indicating patients who are
most likely to benefit from nelarabine therapy are needed.
Here, we used an approach that combined data from the large
pharmacogenomics screens Cancer Therapeutics Response Portal
(CTRP)15, Cancer Cell Line Encyclopedia (CCLE)16, and Geno-
mics of Drug Sensitivity in Cancer (GDSC)17 with data from an
ALL cell line panel derived from the Resistant Cancer Cell Line
(RCCL) collection and patient data to investigate the mechanisms
underlying the discrepancy in the nelarabine sensitivity between
T-ALL and B-ALL.
The results show that low expression of Sterile alpha motif and
histidine-aspartic acid domain-containing protein 1 (SAMHD1)
in T-ALL cells is a key determinant of nelarabine sensitivity and
that SAMHD1 is a potential biomarker and therapeutic target for
the improvement of nelarabine-based therapies for both T-ALL
and B-ALL patients.
Results
Gene expression comparison between T-ALL and B-ALL cells.
To identify potential differences between T-ALL and B-ALL that
may explain the observed discrepancies in nelarabine sensitivity,
we started by analysing data derived from the large pharmaco-
genomics databases CCLE16, Cancer Therapeutics Response
Portal (CTRP)15, and Genomics of Drug Sensitivity in Cancer
(GDSC)17. The CCLE contained data derived from 34 leukaemia
cell lines (18 B-ALL, 16 T-ALL) and the GDSC from 38 leukae-
mia cell lines (21 B-ALL, 17 T-ALL), with an overlap of 19 cell
lines (Supplementary Table 1). The CCLE and CTRP used the
same cell line panel for their studies15.
Nelarabine was tested in 24 ALL (11 B-ALL, 13-T-ALL) cell
lines in the CTRP (Supplementary Table 2). In agreement with
the available literature5,6,18,19, nelarabine displayed higher activity
in T-ALL than in B-ALL cell lines (Supplementary Fig. 1A,
Supplementary Table 2).
Initially, we compared transcriptomics data (mRNA abun-
dance) between T-ALL and B-ALL cell lines. Substantial
proportions of transcripts displayed significant differences (P <
0.05) in their abundance levels between T-ALL and B-ALL cells in
the GDSC (3,998/ 22.5% of 17,735 transcripts), CCLE (8,498/
42.1% of 20,172 transcripts), and CTRP (4,507/ 24.3% of 18,539
transcripts) (Supplementary Data 1). Gene expression heatmaps
illustrated these differences (Supplementary Fig. 1), but manual
analysis of the top differentially regulated genes did not result in
the identification of candidate genes, whose expression seemed
likely to be responsible for the observed differences in nelarabine
sensitivity.
A pathway analysis using the PANTHER database (Protein
ANalysis THrough Evolutionary Relationships, http://pantherdb.
org)20 also did not reveal processes that may underlie the
increased nelarabine sensitivity of T-ALL cells (Supplementary
Fig. 1, Supplementary Data 2). As expected, B-cell- and T-cell-
specific processes featured prominently among the most strongly
differentially regulated pathways.
SAMHD1 levels correlate with nelarabine resistance. The cor-
relation of transcriptomics data with the nelarabine drug
response, represented as AUC, identified SAMHD1 as the gene,
whose expression displayed the most significant direct correlation
(Supplementary Data 3). Analysis of SAMHD1 expression
exclusively in either the B-ALL or T-ALL subset also showed a
highly significant direct correlation with the nelarabine AUC
(Supplementary Data 3). Furthermore, when we correlated drug
AUCs with SAMHD1 expression, nelarabine displayed the most
significant direct correlation with SAMHD1 expression across
all ALL cell lines, the second most significant direct correlation
with SAMHD1 expression in the B-ALL cell lines, and the third
most significant direct correlation with SAMHD1 expression in
the T-ALL cell lines (Supplementary Data 4).
SAMHD1 levels are lower in T-ALL than in B-ALL cells.
SAMHD1 is a deoxynucleotide triphosphate (dNTP) hydrolase
that cleaves physiological dNTPs and triphosphorylated nucleo-
side analogues21–25. It was previously shown to interfere with
the activity of anti-cancer nucleoside analogues including
nelarabine23,24,26. If SAMHD1 was responsible for the differences
observed in nelarabine sensitivity between T-ALL and B-ALL, T-
ALL cells would be expected to express lower levels of SAMHD1.
Indeed, the SAMHD1 expression (mRNA abundance) levels were
significantly lower in T-ALL than in B-ALL cell lines in all three
databases (Fig. 1a). Similar findings were detected in a gene
expression dataset derived from blasts of 306 ALL (222 B-ALL, 84
T-ALL) patients27,28 (Fig. 1b). Further analysis revealed a reduced
expression of SAMHD1 in T-ALL in general but more pro-
nounced in the thymic and mature immunophenotypic subtype
(Supplementary Fig. 2A). On the genetic level, some B-ALL
subgroups like for example Philadelphia (Ph)-like patients display
a gene expression pattern of SAMHD1 that is equally low as seen
in T-ALL (Supplementary Fig. 2B).
SAMHD1 is a determinant of nelarabine sensitivity in ALL. A
number of other gene products have been described to be
involved in the transport, activation, and metabolism of nucleo-
side analogues such as nelarabine, including DCK, DGUOK,
SLC29A1 (ENT1), SLC29A2 (ENT2), NT5C, NT5C2, PNP,
RRM1, RRM2 and SLC22A4 (OCTN1)19,29. While statistically
significant differences in the expression of some of the respective
genes were noted between B-ALL and T-ALL cell lines in some
of the three datasets, none was consistent across all three and
none was as robust as in the expression of SAMHD1 (Fig. 1c,
Supplementary Fig. 3). In patient samples, SAMHD1 also dis-
played the most significant difference in expression levels between
B-ALL and T-ALL (Supplementary Fig. 3). Moreover, only the
expression of SAMHD1 correlated with the nelarabine AUC in
the CTRP dataset (Fig. 2, Supplementary Fig. 4). This shows that
SAMHD1 is a critical determinant of nelarabine efficacy in ALL
and that low SAMHD1 levels critically contribute to the specific
nelarabine sensitivity of T-ALL cells.
SAMHD1 is no determinant of cytarabine sensitivity in ALL.
Cellular SAMHD1 levels have previously been shown to critically
determine cytarabine efficacy in acute myeloid leukaemia (AML)
cells23,24,30 and SAMHD1 expression levels are lower in T-ALL
than in AML cells (Supplementary Fig. 5). The CTRP and GDSC
contained data on cytarabine activity. In contrast to AML cells,
however, there was no difference in the cytarabine sensitivity
between B-ALL and T-ALL cell lines and no correlation between
SAMHD1 expression and cytarabine sensitivity in ALL cells
(Fig. 2, Supplementary Fig. 6). Hence, the effect of SAMHD1 on
nucleoside analogue activity depends on the tissue context.
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SAMHD1 mRNA levels reflect protein levels in ALL cell lines.
To further investigate the role of SAMHD1 on nelarabine and
cytarabine efficacy in ALL, we assembled a panel consisting of 15
B-ALL and 11 T-ALL cell lines from the RCCL collection31
(Supplementary Table 3). Firstly, we investigated the extent to
which cellular SAMHD1 mRNA levels are indicative of cellular
protein levels. Western blot analyses confirmed that the RCCL
T-ALL cell lines generally display lower SAMHD1 protein levels
than the RCCL B-ALL cell lines (Fig. 3a, Supplementary Fig. 7).
However, quantitative western blot analysis and quantitative PCR
(qPCR) showed that cellular SAMHD1 mRNA levels do not
always directly correlate with cellular SAMHD1 protein levels
(Fig. 3b). This is likely to reflect the complexity of the regulation
of protein levels, which are determined by transcription and
Fig. 1 SAMHD1 levels differ between T-ALL and B-ALL. Comparison of SAMHD1 expression (mRNA abundance) levels in T-ALL and B-ALL cell lines from
the CTRP, CCLE, and GDSC (a) and in blasts from leukaemia patients (b). c Comparison of the expression of other genes known to affect nucleoside analogue
activity based on CTRP data. Respective CCLE and GDSC data are provided in Supplementary Fig. 2. *p-values for the comparison B-ALL vs. T-ALL.
Fig. 2 Comparison of nelarabine (CTRP) and cytarabine (CTRP, GDSC) sensitivity between B-ALL and T-ALL cell lines and correlation of SAMHD1
mRNA levels with the nelarabine and cytarabine sensitivity (expressed as AUC) across all B-ALL and T-ALL cell lines. Pearson’s r values and respective
p-values are provided. Respective data on the correlation of SAMHD1 expression with drug sensitivity exclusively for B-ALL and T-ALL cell lines are
provided in Supplementary Fig. 3 (nelarabine) and Supplementary Fig. 4 (cytarabine).
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translation efficacy, factors that control mRNA stability (e.g.
microRNAs and proteins that control mRNA degradation), and
post-translational modifications that promote (proteasomal)
protein degradation32–37. Moreover, mutations may affect
SAMHD1 function, as demonstrated in patients with chronic
lymphocytic leukaemia and colorectal cancer38,39. However, the
only ALL cell line with a SAMHD1 mutation was Jurkat, which
harboured an R611* nonsense mutation based on GDSC data.
SAMHD1 mRNA and protein levels in the RCCL are correlated
with SAMHD1 mRNA levels in the corresponding cell lines from
CTRP, CCLE and GDSC (Supplementary Fig. 8). Hence,
SAMHD1 mRNA levels, largely predict SAMHD1 protein levels,
which is in line with previous findings30.
Next, the sensitivity of the RCCL ALL cell lines was tested
against arabinosylguanine (AraG), the product of the prodrug
nelarabine40 and cytarabine. The results were in agreement with
the CTRP data showing that T-ALL cell lines were significantly
more sensitive to AraG than B-ALL cell lines (Fig. 4, Supple-
mentary Table 3). Notably, there was a significant correlation
between the nelarabine AUCs in the CTRP and the AraG IC50s
in the RCCL panel among the cell lines that were present in both
datasets (Supplementary Fig. 9). In contrast to the CTRP and
GDSC data that had not indicated a difference between the
cytarabine sensitivity of T-ALL- and B-ALL- cells, T-ALL cell
lines displayed a trend indicating increased sensitivity to
cytarabine (P= 0.055) (Fig. 4). SAMHD1 protein levels displayed
a significant correlation with the AraG concentrations that
reduced cell viability by 50% (IC50) in all ALL cell lines and the
lineage-specific subanalyses (Fig. 4). In contrast, a significant
correlation between SAMHD1 protein levels and cytarabine
activity was only detected across all ALL cell lines but not when
only B-ALL or T-ALL cell lines were considered (Fig. 4).
SAMHD1 mRNA levels were correlated with the AraG IC50
across all ALL cell lines and T-ALL cell lines but not B-ALL cell
lines (P= 0.1335) (Fig. 4). No significant correlation was detected
between the SAMHD1 mRNA levels and the cytarabine IC50 in
the RCCL ALL cell lines (Fig. 4).
Taken together, these results confirm the CTRP data in
showing that cellular SAMHD1 levels determine ALL sensitivity
against AraG, the product of nelarabine, and that low SAMHD1
levels in T-ALL cells are associated with specific nelarabine/
Ara-G activity in this lineage. In contrast to the CTRP and
GDSC data, the additional experimental analyses in the RCCL
ALL cell line panel suggest that SAMHD1 levels may also affect
cytarabine activity in ALL, albeit to a lower degree than AraG
activity.
Fig. 3 SAMHD1 protein and mRNA levels in the RCCL panel of B-ALL and T-ALL cell lines. a Representative Western blots indicating protein levels of
total SAMHD1 and phosphorylated SAMHD1 (p-SAMHD1). GAPDH was used as loading control. b Quantitative SAMHD1 protein levels are shown as
means ± SD from three independent experiments (quantified using near-infrared Western blot images to determine the ratio SAMHD1/ GAPDH relative to
the positive control THP-1, an acute myeloid leukaemia cell line characterised by high cellular SAMHD1 levels [Schneider et al.30]. SAMHD1 mRNA
abundance levels are shown as means ± SD from three technical replicates (as determined by qPCR, relative to cell line ROS-50) in B-ALL and T-ALL
cell lines. Unpaired two-tailed Student’s t-tests were used to compare means (represented as horizontal lines ± SEM) of SAMHD1 protein or mRNA levels
in B-ALL and T-ALL cells.
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SAMHD1 depletion sensitises ALL cells to AraG. To further
investigate the functional role of SAMHD1 in determining AraG
and cytarabine activity in ALL cells, we depleted SAMHD1 using
virus-like particles containing Vpx as previously described30,41.
Vpx is a protein encoded by HIV-2 and certain SIV strains that
mediates proteasomal SAMHD1 degradation41–43. Vpx virus-like
particles resulted in the sensitisation of ALL cells to AraG and
cytarabine but exerted much more pronounced effects on the
activity of AraG (Fig. 5a).
In the ALL cell lines MHH-CALL-4, SEM, and TANOUE, the
AraG IC50s were between 37.5- and 101-fold lower following
exposure to Vpx virus-like particles compared to Vpr virus-like
particles, which served as negative controls. In contrast, Vpx
virus-like particles only reduced the cytarabine IC50s by 5- and
7-fold lower in these cell lines.
Different role of SAMHD1 as resistance factor in ALL and
AML. In AML cells, SAMHD1 has been described as a critical
regulator of cytarabine activity30. Since Vpx virus-like particle-
mediated SAMHD1 depletion had resulted in a more pronounced
sensitisation of ALL cells to AraG than to cytarabine, we further
compared the effect of the presence or absence of functional
SAMHD1 on the activity of these structurally related nucleoside
analogues in these two types of acute leukaemia. Cell models
included the SAMHD1-expressing AML cell line THP-1 and
its subline, in which the SAMHD1 gene had been disrupted
by CRISPR/Cas9 (THP-1- KO). Further, we investigated the
SAMHD1 low/ non- expressing cell lines HEL (AML) and Jurkat
(T-ALL) and their respective sublines transduced either with wild-
type (WT) SAMHD1 or the triphosphohydrolase-defective mutant
SAMHD1-D311A. In the AML cell lines, absence of functional
SAMHD1 was associated with a 60-fold (THP-1/ THP-1-KO) and
6583-fold (HEL-SAMHD1_WT/HEL-SAMHD1_D311A) sensiti-
sation to cytarabine, but only a 5.6- and 6.0-fold sensitisation to
AraG (Fig. 5b). The T-ALL cell line Jurkat-SAMHD1_D311A was
101 times more sensitive to AraG than Jurkat-SAMHD1_WT,
while JURKAT-SAMHD1_D311A was only 10 times more sen-
sitive to cytarabine (Fig. 5b). In summary, SAMHD1 activity
critically regulates cytarabine activity but has a much lower impact
on AraG in AML cells. The opposite effect is observed in ALL
cells, in which SAMHD1 crucially determines AraG activity but
exerts substantially less pronounced effects on cytarabine activity.
This further confirms that the cellular background critically
determines the importance of SAMHD1 as regulator of nucleoside
activity.
High SAMHD1 promoter methylation in T-ALL cell lines.
SAMHD1 levels may be regulated by SAMHD1 promoter
methylation in leukaemia cells44,45. Therefore, we compared
SAMHD1 promoter methylation in T-ALL and B-ALL cell lines
through amplification of a single PCR product (993-bp) corre-
sponding to the promoter sequence after HpaII digestion. Results
indicated that the SAMHD1 promoter was methylated in all
T-ALL cell lines but one (MOLT-16) (Fig. 6a), which was the only
T-ALL cell line characterised by high SAMHD1 mRNA and
protein levels (Fig. 3) and low AraG sensitivity (Supplementary
Table 3). In contrast, SAMHD1 promoter methylation was only
observed in two out of 15 B-ALL cell lines (NALM-6, TOM-1)
(Fig. 6a). In agreement, SAMHD1 promoter methylation was also
significantly higher in T-ALL than in B-ALL cells in the GDSC
and inversely correlated with SAMHD1 expression (Fig. 6b).
Notably, global DNA methylation did not differ between T-ALL
and B-ALL cell lines (Fig. 6c), suggesting lineage-specific differ-
ences. Taken together, this suggests that the differences in cellular
SAMHD1 levels observed between T-ALL and B-ALL cell lines
are to a large extent caused by differences in SAMHD1 promoter
methylation.
Fig. 4 AraG and cytarabine concentrations that reduce the viability of the RCCL ALL cell lines by 50% (IC50) and correlation of the IC50s with the
cellular SAMHD1 protein or mRNA levels. Numerical data are provided in Supplementary Data 4. Closed circles and error bars represent means ± SD of
three independent experiments, each performed in three technical replicates. Linear regression analyses were performed using GraphPad Prism.
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Discussion
Similar chemotherapeutic agents are used to treat T-ALL and
B-ALL. However, nelarabine is specifically used for relapsed
T-ALL3,7–12. Although it had been known for decades that
nelarabine is more active in T-ALL than in B-ALL cells6,46, the
underlying mechanisms had remained elusive.
Here, we used an approach combining data derived from
large pharmacogenomics screens (CTRP, CCLE, GDSC), an
RCCL-derived ALL cell line panel, and patient data and found
that cellular SAMHD1 levels critically determined ALL cell
sensitivity to nelarabine and AraG. Nelarabine is metabolised
into AraG, which is then triphosphorylated by cellular kinases
Fig. 5 Effect of SAMHD1 on nelarabine and cytarabine sensitivity in ALL and AML cells. a Dose-response curves of AraG- and cytarabine-treated ALL
cell lines in the absence or presence of Vpx virus-like particles (cause SAMHD1 depletion), or Vpr virus-like particles (negative) controls. Concentrations
that reduce ALL cell viability by 50% (IC50s) and Western blots confirming SAMHD1 depletion are provided. Each symbol represents the mean ± SD of
three technical replicates of one representative experiment out of three. b Effects of AraG and cytarabine on AML cell lines in the absence or presence of
functional SAMHD1. In the SAMHD1-expressing AML cell line THP-1, the SAMHD1 gene was disrupted by CRISPR/Cas9 (THP1-KO). The non-SAMHD1
expressing AML cell line HEL and the non-SAMHD1 expressing ALL cell line JURKAT were transduced with wild-type SAMHD1 (SAMHD1_WT) or the
triphosphohydrolase-defective SAMHD1 mutant D311A (SAMHD1_D311A). Dose-response curves, drug concentrations that reduce cell viability by 50%
(IC50s), and Western blots confirming SAMHD1 protein levels are provided. Each symbol represents the mean ± SD of three independent experiments,
each performed in three technical replicates.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-1052-8
6 COMMUNICATIONS BIOLOGY |           (2020) 3:324 | https://doi.org/10.1038/s42003-020-1052-8 | www.nature.com/commsbio
into the active form40. SAMHD1 is a deoxynucleotide tripho-
sphate (dNTP) hydrolase that cleaves and inactivates tripho-
sphorylated nucleoside analogues including triphosphorylated
AraG23–25,45. Moreover, T-ALL cells were characterised
by substantially lower SAMHD1 levels than B-ALL cells.
Previous studies had demonstrated an association between
AraG efficacy and AraG triphosphate levels in leukaemia cells,
but the mechanism determining AraG triphosphate levels had
remained unknown6,19,46,47. Hence, SAMHD1 is the missing
link explaining the discrepancy in nelarabine sensitivity
between T-ALL and B-ALL.
Notably, SAMHD1 has also been shown to promote DNA
damage repair including damage induced by the topoisomerase
inhibitors camptothecin and etoposide48. Thus, SAMHD1-
mediated repair of nelarabine/ AraG-induced DNA damage
may potentially also contribute to the increased nelarabine/
AraG resistance associated with high SAMHD1 levels in ALL
cells. However, SAMHD1 expression was not associated with
generally increased resistance to DNA damaging agents in the
CTRP (Supplementary Data 4). The AUC of the PARP inhibitor
veliparib was correlated with SAMHD1 expression, but the
AUC of the PARP inhibitor olaparib was not. The AUCs of
etoposide and other prominent DNA damaging agents such
as the alkylating agents temozolomide, ifosfamide, and dacar-
bazine and the nucleoside analogue 5-fluorouracil also were
also not correlated with SAMHD1 expression, and the AUCs of
the alkylating agents cyclophosphamide and chlorambucil,
the nucleoside analogue gemcitabine, the DNA cross-linker
mitomycin C, and the topoisomerase inhibitor doxorubicin
displayed a significant inverse correlation to SAMHD1 expres-
sion (Supplementary Data 4). These data do not suggest that
SAMHD1 interferes with the effects of anti-cancer drugs pre-
dominantly via promotion of DNA damage repair.
Data derived from the RCCL ALL cell line panel as well as
from the GDSC indicate that the differences in SAMHD1
expression observed between T-ALL and B-ALL cells are at least
in part the consequence of higher SAMHD1 promoter methyla-
tion in T-ALL than in B-ALL cells. Thus, SAMHD1 expression
levels and SAMHD1 promoter methylation are potential
biomarkers of nelarabine sensitivity that deserve further clinical
investigation. Based on our current data, patients suffering from
ALL characterised by high SAMHD1 expression are unlikely to
benefit from therapy using nelarabine and may be better treated
with ribose-based thiopurines that are no SAMHD1 substrates,
such as 6-thioguanine or 6-mercaptopurine49.
SAMHD1 depletion sensitised ALL cells to AraG, indicating
that SAMHD1 may also serve as a therapeutic target to improve
nelarabine therapies in ALL patients. Notably, both T-ALL and
B-ALL patients may benefit from SAMHD1 inhibition in com-
bination with nelarabine therapy. Interestingly, the effect of
SAMHD1 on the activity of nucleoside analogues varied sub-
stantially between different forms of leukaemia. SAMHD1 was
previously shown to critically determine the activity of the
nucleoside analogue cytarabine in AML23,24,30. Compared to the
pronounced effects of SAMHD1 on nelarabine/ AraG activity in
ALL, however, SAMHD1 exerted only minor effects on the
activity of cytarabine in this leukaemia type. Interestingly, the
situation was reversed in AML cells, where SAMHD1 critically
affected cytarabine activity but had much lower impact on
AraG. These findings are important, because they illustrate that,
despite a general trend in the biomedical community towards
tumour-agnostic approaches, which consider cancer-specific
alterations independently of the cancer type50,51, a much more
in depth understanding of the molecular make-up of cancer cells
will be required, before therapy decisions can be entirely based
on molecular markers without taking the cancer entity into
consideration.
In conclusion, our data indicate that cellular SAMHD1 levels
critically determine ALL cell sensitivity to nelarabine/ AraG
and that T-ALL cells display lower SAMHD1 levels than B-
ALL. This provides a solution to a decades old conundrum
providing a mechanistic explanation for the higher nelarabine
sensitivity of T-ALL cells compared to B-ALL cells. Hence,
SAMHD1 has potential as a biomarker for the more accurate
identification of ALL patients, who are likely to benefit from
nelarabine therapy. Moreover, SAMHD1 is a therapeutic target
for the design of improved nelarabine-based treatment strate-
gies for ALL patients.
Fig. 6 SAMHD1 promoter methylation in ALL cell lines. a Analysis of SAMHD1 promoter methylation in the RCCL cell line panel through amplification of a
single PCR product (993-bp) corresponding to the promoter sequence after HpaII digestion. A 0.25-kb fragment of the GAPDH gene lacking HpaII sites
was PCR-amplified using the same template DNA served as loading control. b GDSC data indicating SAMHD1 promoter methylation in B-ALL and T-ALL
cell lines and correlation of SAMHD1 promoter methylation and SAMHD1 expression across all ALL cell lines. c GDSC data indicating the level of global
methylation in B-ALL and T-ALL cell lines.
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Methods
Analysis of data from pharmacogenomics screens. ALL cell line drug sensitivity
data and RMA-normalised gene expression values were obtained from the CCLE
(2015 release, https://portals.broadinstitute.org/ccle), which contains data from 34 ALL
cell lines (18 B-ALL and 16 T-ALL)16, GDSC (2016 release, https://www.cancerrxgene.
org/; 21 B-ALL/ 17 T-ALL cell lines)17, and CTRP (version 2, 2015 release, https://ocg.
cancer.gov/programs/ctd2/data-portal; 11 B-ALL/ 13 T-ALL cell lines) 15.
Gene expression was compared using the Mann-Whitney U (Wilcoxon) test for
independent groups. Multiple test correction of p-values was performed using the
Benjamini–Hochberg (BH) procedure52, with a false discovery rate (FDR) of 0.05
(BH= (rank/n) × FDR, where n= the total number of genes compared). Gene
expression levels between B-ALL and T-ALL cell lines were visualised using the
ggboxplot function in R. Heatmaps showing gene expression levels were generated
using the ggplot2 package in R.
In all, 36 of the ALL cell lines (19 B-ALL, 17 T-ALL) in the GDSC and 22 ALL
cell lines (10 B-ALL, 12 T-ALL) in the CTRP were treated with cytarabine. 23 ALL
cell lines (11 B-ALL, 12 T-ALL) in the CTRP were treated with nelarabine. Scatter
plots and their associated Pearson correlations for each drug AUCs against gene
expression were calculated using the ggplot2 package in R.
Expression of 18,542 genes was correlated with the nelarabine AUC in ALL cell
lines and SAMHD1 expression was correlated with the AUC values of 441 drugs
tested in ALL cell lines using the CTRPv2 dataset. Pearson correlation coefficients
were calculated using the cor.test function in R. P-values for each correlation were
ranked and multiple test correction was performed (Benjamini–Hochberg
procedure, FDR= 0.05).
Pathway analysis was performed using the PANTHER (version 14.1)
Overrepresentation Test [Mi et al.20] based on genes significantly differentially
expressed in B-ALL and T-ALL cell lines after Benjamini–Hochberg p-value
correction (FDR= 0.05). Fisher’s exact test was applied to calculate over- vs.
underrepresentation of classes. Heatmaps were prepared using the ggplot2
package in R.
Beta values for CpG sites in the SAMHD1 promoter derived from the GDSC
(Gene Expression Omnibus ID GSE68379) were correlated with SAMHD1
expression in ALL cell lines.
Analysis of patient data. SAMHD1 gene expression was analyzed in publicly
available Microarray data of 306 primary adult B- and T-ALL patients (Gene
Expression Omnibus ID GSE66006)28. The median percentage of leukemic cells in
the samples was 90%.
Drugs. Cytarabine was purchased from Tocris Biosciences (via Bio-Techne GmbH,
Wiesbaden, Germany), AraG from Jena Bioscience (Jena, Germany).
Cell lines. The human ALL cell lines 697, ALL-SIL, BALL-1, CTV-1, GRANTA-
452, HAL-01, HSB-2, JURKAT, KE-37, MHH-CALL-4, MN-60, MOLT-4, MOLT-
16, NALM-6, NALM-16, P12-ICHIKAWA, REH, ROS-50, RPMI-8402, RS4;11,
SEM, TANOUE, and TOM-1 and the AML cell lines THP-1 and HEL were
obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellk-
ulturen GmbH, Braunschweig, Germany). The ALL cell lines CCRF-CEM and
JJHan were received from ATCC (Manassas, VA, US) and the ALL cell line
KARPAS231 from Cambridge Enterprise Ltd. (Cambridge, UK).
THP-1 cells deficient in SAMHD1 (THP-1 KO) and control cells (THP-1 Ctr.)
were generated using CRISPR/Cas9 approach as previously described30,45,53. THP-
1 cells were plated at a density of 2 × 105 cells per ml. After 24 h, 2.5 × 106 cells were
resuspended in 250 µl Opti-MEM, mixed with 5 µg CRISPR/Cas plasmid DNA,
and electroporated in a 4-mm cuvette using an exponential pulse at 250 V and 950
mF utilizing a Gene Pulser electroporation device (Bio-Rad Laboratories). We used
a plasmid encoding a CMV-mCherry-Cas9 expression cassette and a human
SAMHD1 gene specific gRNA driven by the U6 promoter. An early coding exon of
the SAMHD1 gene was targeted using the following gRNA construct: 5′-
CGGAAGGGGTGTTTGAGGGG-3′. Cells were allowed to recover for 2 days in
six-well plates filled with 4 ml medium per well before being FACS sorted for
mCherry-expression on a BD FACS Aria III (BD Biosciences). For subsequent
limiting dilution cloning, cells were plated at a density of 5, 10, or 20 cells per well
of nine round-bottom 96-well plates and grown for 2 weeks. Plates were scanned
for absorption at 600 nm and growing clones were identified using custom software
and picked and duplicated by a Biomek FXp (Beckman Coulter) liquid handling
system.
The HEL and JURKAT SAMHD1-WT and SAMHD1-D311A cell lines were
generated by co-transfection of the packaging vector pPAX2 (Addgene), either
pHR-SAMHD1-WT or pHR-SAMHD1-D311A and a plasmid encoding VSV-G, as
previously described45. All cell lines were routinely tested for Mycoplasma, using
the MycoAlert PLUS assay kit from Lonza, and were authenticated by short
tandem repeat profiling, as described elsewhere.
All cell lines were cultured in IMDM (Biochrom) supplemented with 10% FBS
(Sigma-Aldrich), 4 mM L-glutamine (Sigma-Aldrich), 100 IU per ml penicillin
(Sigma-Aldrich), and 100 µg per ml streptomycin (Sigma-Aldrich) at 37 °C in a
humidified 5% CO2 incubator.
Viability assay. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay modified after Mosman54, as previously
described55. Cells suspended in 100 µL cell culture medium were plated per well in
96-well plates and incubated in the presence of various drug concentrations for 96
h. Then, 25 µL of MTT solution (2 mg/mL (w/v) in PBS) were added per well, and
the plates were incubated at 37 °C for an additional 4 h. After this, the cells were
lysed using 200 µL of a buffer containing 20% (w/v) sodium dodecylsulfate in 50%
(v/v) N,N-dimethylformamide with the pH adjusted to 4.7 at 37 °C for 4 h.
Absorbance was determined at 570 nm for each well using a 96-well multiscanner.
After subtracting of the background absorption, the results are expressed as per-
centage viability relative to control cultures which received no drug. Drug con-
centrations that inhibited cell viability by 50% (IC50) were determined using
CalcuSyn (Biosoft, Cambridge, UK).
Western blotting. Western blotting was performed as previously described
[Schneider et al.30]. Cells were lysed in Triton X-100 sample buffer and proteins
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Pro-
teins were blotted on a nitrocellulose membrane (Thermo Scientific). The fol-
lowing primary antibodies were used at the indicated dilutions: SAMHD1
(Proteintech, 12586-1-AP, 1:1,000), β-actin (BioVision, 3598R-100, 1:5,000),
pSAMHD1 (Cell Signaling, 89930S, 1:1,000), and GAPDH (Trevigen, 2275-PC-
10C, 1:5,000). Visualisation and quantification were performed using IRDye-
labeled secondary antibodies (LI-COR Biotechnology, IRDye®800CW Goat anti-
Rabbit, 926-32211, 1:40,000) according to the manufacturer’s instructions. Band
volume analysis was conducted by Odyssey LICOR. Uncropped blots are pre-
sented in Supplementary Fig. 10. SAMHD1 quantification was performed using a
protein extract of the AML cell line THP-1 as internal control (Supplementary
Fig. 10, Supplementary Data 5).
mRNA analysis. RNA extraction and TaqMan-based mRNA quantification of
SAMHD1 (assay no. Hs00210019_m1) and RNaseP (TaqMan® RNaseP Assay
(A30065)) as endogenous reference control were performed according to the
manufactures protocol (Applied Biosystems). Total RNA was extracted using the
RNeasy Kit from Qiagen and stored at −80 °C until use. Relative quantitative PCR
analyses were performed on the QuantStudio 7 Flex Real-Time PCR System
(Applied Biosystems). SAMHD1 mRNA expression levels were quantified by using
the ΔΔCt method with RNaseP mRNA as an endogenous reference control. All
samples were run in triplicate. Data analysis was conducted using the QuantStudio
System Software (Applied Biosystems).
SAMHD1 promoter methylation. SAMHD1 promoter methylation was deter-
mined as previously described45. SAMHD1 promoter contains five HpaII sites
surrounding the transcription start site44. Methylation of the HpaII sites in the
SAMHD1 promoter would prevent digestion by the HpaII, and the intact sequence
would serve as a template for PCR amplification using SAMHD1 promoter-specific
primers that flank the HpaII sites. To measure methylation of the SAMHD1 pro-
moter genomic DNA was treated with the methylation-sensitive HpaII endonu-
clease or left untreated as described previously with some modifications44. PM3.
fwd: TTCCGCCTCATTCGTCCTTG and PM3.rev: GGTTCTCGGGCTGTCAT
CG were used as SAMHD1 promoter-specific primers. A single PCR product
(993-bp) corresponding to the SAMHD1 promoter sequence was obtained from
untreated genomic DNA and treated DNA from cells with methylated but not from
cells with unmethylated SAMHD1 promoter. To serve as input control, a 0.25-kb
fragment of the GAPDH gene lacking HpaII sites was PCR-amplified using the
same template DNA44. Uncropped agarose gels are shown in Supplementary
Fig. 10.
SAMHD1 depletion using Vpx virus-like particles. Cells were spinoculated with
VSV-G pseudotyped virus-like particles carrying either Vpx or Vpr from SIV-
mac251, produced by co-transfection of 293T cells with pSIV3+ gag pol expres-
sion plasmids and a plasmid encoding VSV-G as previously described 30,44.
Statistics and reproducibility. Statistical data analyses were performed in
GraphPad Prism version 7. Population means were compared using unpaired two-
tailed Student’s t-tests. Data are presented as means ± standard deviation (S.D.).
Specific information on the number and nature of replicates is provided in the
figure legends. Correlation analyses were performed using linear regression in
GraphPad Prism resulting in r2 as a measure for goodness-of-fit and the P value,
which is calculated from an F test, indicating whether the slope is significantly
different from zero.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All source data underlying the graphs, which are not based on publicly available data
from CCLE, CTRP, GDSC and patient gene expression data (Gene Expression Omnibus
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paper or available from the corresponding authors upon reasonable request.
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